Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Summary

The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy that is approved for colorectal cancer, can help people whose cancer has spread or returned after treatments taken before. To join the study, participants must meet the following conditions: Be 18 years or older. Have colorectal cancer that has spread to other parts of your body. Be in good enough health to receive study treatment.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Intestinal Neoplasms
• Gastrointestinal Neoplasms
• Digestive System Neoplasms
• Neoplasms by Site
• Digestive System Diseases
• Gastrointestinal Diseases
• Colonic Diseases
• Intestinal Diseases
• Rectal Diseases
• Colorectal Neoplasms

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Pfizer

Last updated on ClinicalTrials.gov

October 8, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

+77 more sites listed on ClinicalTrials.gov